Shares of Cadila Healthcare surged 5 per cent today as Zydus Cadila received the US health regulator's nod to market levofloxacin injection, used to treat bacterial infections.
The stock gained 5 per cent to settle at Rs 494.55 on BSE. During the day, it soared 7.18 per cent to Rs 504.80 -- its 52-week high.
At NSE, shares of the company jumped 4.93 per cent to close at Rs 494.20.
The company's market valuation went up by Rs 2,416.19 crore to Rs 50,629.19 crore.
On the volume front, 4.71 lakh shares of the company were traded on BSE, and over 38 lakh shares changed hands at NSE during the day.
Cadila Healthcare is the group firm of Zydus Cadila.
The company has received final approval from the US Food and Drug Administration (USFDA) to market levofloxacin injection, 500 mg/20mL and 750mg/30 mL, Cadila Healthcare said in a BSE filing.
The company will manufacture the product at its Moraiya plant in Gujarat.
Disclaimer: No Business Standard Journalist was involved in creation of this content
